Dr. Peter Cho’s section focused on cough in ILDs (on behalf of Strados Labs) from 28:52 – 39:40. Interstitial lung disease (ILD) represents a diverse group of disorders characterized by infiltration of lung parenchyma with extracellular matrix, leading to...
Cough monitoring has emerged as an increasingly common practice in research studies and drug development in recent years to objectively measure changes in subjects’ cough. As drug developers consider including cough frequency as an endpoint in their studies,...
In research studies and healthcare settings, minimizing patient burden is essential for reliable data collection with wearables and devices. At Strados Labs, we understand the importance of these factors with the RESP® Biosensor, which is designed to continuously...
Increased importance has been placed in recent years on the ability of idiopathic pulmonary fibrosis (IPF) treatments to impact how patients feel and function, beyond survival (Raghu, et al., 2024). In IPF, one of the most burdensome symptoms impacting how patients...
The Leicester Cough Questionnaire (LCQ)1 is a self-reporting tool developed by S.S. Birring and others to evaluate the impact of chronic cough on a patient’s quality of life. Chronic cough,2 which impacts between 10-20% of the US population,3 is a cough that can...
In November 2023, Merck’s chronic cough drug, gefapixant, faced a decisive setback from the FDA Advisory Committee. The concerns highlighted insufficient evidence for the drug providing a clinically meaningful benefit to adults with refractory chronic cough...
